NeurologyLive® Mind Moments®

<div> <p>Welcome to this special episode of the <em>NeurologyLive</em>® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.</p><p>In this episode, "Key Challenges Facing Neurology in the Year Ahead," Natalia Rost, MD, President of the American Academy of Neurology (AAN), Stroke Division Chief at Massachusetts General Hospital, and Professor of Neurology at Harvard Medical School, joins NeurologyLive to discuss the top clinical priorities shaping neurology in 2026.</p><p>Throughout the discussion, Rost outlines the most urgent unmet needs across neurology, including expanding equitable access to care, integrating preventive neurology into routine practice, strengthening the workforce, and closing persistent evidence gaps. She explains how the AAN Brain Health Initiative provides a practical framework for embedding brain health into everyday clinical encounters. The conversation also explores the growing role of biomarkers, imaging, and digital tools in care delivery, where innovation may be outpacing evidence, and how the Academy aims to guide ethical and evidence based implementation while addressing ongoing health equity gaps.</p><p>Episode Breakdown:</p></div><ul> <li> <strong>1:10</strong> – Most urgent unmet clinical needs facing neurology in 2026</li> <li> <strong>3:25</strong> – Implementing brain health in everyday clinical practice</li> <li> <strong>8:00</strong> – Role of biomarkers, imaging, and digital tools in routine neurologic care</li> <li> <strong>11:20</strong> – AAN priorities for education, advocacy, and clinical guidance in 2026</li> <li> <strong>14:25</strong> – Major clinical gaps driving health inequities in neurologic care and outcomes</li> </ul><div> <br>Thanks for listening to the <em>NeurologyLive</em>® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit <a href="http://neurologylive.com/">neurologylive.com</a>.</div>

<div> <p>Welcome to the <em>NeurologyLive</em>® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.</p><p>In this Mind Moments episode, Amaal Starling, MD, FAHS, FAAN, joins the podcast to provide clinical perspective on the INFUSE real world study evaluating IV eptinezumab in adults with migraine who previously found one or more CGRP preventive options ineffective, based on data presented at the 2026 Headache Cooperative of the Pacific Annual Conference. Starling, an associate professor of neurology at Mayo Clinic College of Medicine and a study author on INFUSE, discusses how clinicians should interpret the magnitude of benefit in a high burden population and why IV delivery, including rapid and consistent bioavailability, may help explain early and sustained response. The conversation also explores what the findings suggest for real world care and treatment sequencing, how migraine trials can better capture patient experience through outcomes like good days and PGIC, and what precision medicine research could look like next as the field pushes toward predictive modeling and individualized treatment selection.</p><p><strong>Looking for more Headache &amp; Migraine discussion? Check out the </strong><strong><em>NeurologyLive</em></strong><strong>® </strong><a href="https://www.neurologylive.com/clinical/headache-migraine"><strong>Headache &amp; Migraine clinical focus page</strong></a><strong>.</strong></p><p>Episode Breakdown:</p></div><ul> <li> <strong>1:20</strong> – Interpreting real world response after prior CGRP preventive failure</li> <li> <strong>4:25</strong> – Mechanistic reasons IV eptinezumab may drive early sustained benefit</li> <li> <strong>6:25</strong> – Clinical implications for earlier, more robust treatment sequencing</li> <li> <strong>8:50</strong> – Neurology News Network </li> <li> <strong>11:20</strong> – Integrating good days and Patient Global Impression scales into migraine trial design</li> <li> <strong>15:30</strong> – Future studies needed to advance precision migraine care</li> </ul><div><p><br>The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:</p></div><ul> <li><h1><a href="https://www.neurologylive.com/view/fenebrutinib-meets-primary-end-point-phase-3-comparative-study-teriflunomide-relapsing-ms">Fenebrutinib Achieves Primary End Point in Phase 3 Head-to-Head Trial vs Teriflunomide in Relapsing MS</a></h1></li> <li><h1><a href="https://www.neurologylive.com/view/praxis-submits-ndas-for-ulixacaltamide-essential-tremor-relutrigine-scn2a-scn8a-developmental-epileptic-encephalopathies">Praxis Submits NDAs for Ulixacaltamide in Essential Tremor and Relutrigine in SCN2A/SCN8A Developmental Epileptic Encephalopathies</a></h1></li> <li><h1><a href="https://www.neurologylive.com/view/efgartigimod-meets-primary-end-point-phase-3-adapt-oculus-study-ocular-myasthenia-gravis">Efgartigimod Meets Primary End Point in Phase 3 ADAPT OCULUS Study of Ocular Myasthenia Gravis</a></h1></li> </ul><div> <br>Thanks for listening to the <em>NeurologyLive</em>® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit <a href="http://neurologylive.com/">neurologylive.com</a>.</div>

<div> <p>Welcome to the <em>NeurologyLive</em>® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.</p><p>In this special <em>Mind Moments</em> episode, Lauren Sansing, MD, MS, FAHA, FANA, Professor of Neurology at Yale School of Medicine, joins the podcast to provide a clinical breakdown of the 2026 International Stroke Conference and its implications for real-world stroke care. Sansing reflects on how this year’s meeting built on prior advances, highlighting expanded global collaboration, greater patient engagement, and a record number of clinical trials presented. The discussion explores which late-breaking studies may influence practice in the coming year, including data on secondary stroke prevention, adjunctive thrombolysis strategies, and evolving patient selection for thrombectomy in extended windows and large core infarcts. Sansing also reviews renewed momentum in neuroprotection research, key updates from the newly released acute ischemic stroke guidelines, emerging pediatric stroke data, and how the conference continues to shape the roadmap for 2027 and beyond.</p><p><strong>Looking for more Stroke discussion? Check out the </strong><strong><em>NeurologyLive</em></strong><strong>® </strong><a href="https://www.neurologylive.com/clinical/stroke"><strong>Stroke clinical focus page</strong></a><strong>.</strong></p><p>Episode Breakdown:</p></div><ul> <li> <strong>1:00</strong> – Biggest moments and structural evolution of ISC 2026</li> <li> <strong>3:15</strong> – Presented practice-changing trial data impacting stroke care</li> <li> <strong>7:05</strong> – Thrombectomy strategy and extended window patient selection</li> <li> <strong>10:40</strong> – Renewed momentum in neuroprotection research</li> <li> <strong>15:20</strong> – Neurology News Network </li> <li> <strong>17:40</strong> – Key updates from the new acute ischemic stroke guidelines</li> <li> <strong>25:00</strong> – A brief look-ahead to ISC 2027</li> </ul><div><p><br>The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:</p></div><ul> <li><h1><a href="https://www.neurologylive.com/view/ptc-withdraws-ataluren-submission-treatment-nonsense-mutation-duchenne-muscular-dystrophy">PTC Withdraws Ataluren Submission as Treatment for Nonsense Mutation Duchenne Muscular Dystrophy</a></h1></li> <li><h1><a href="https://www.neurologylive.com/view/microbiome-targeted-agent-pll001-passes-safety-check-phase-1-2-trial-als">Microbiome-Targeted Agent PLL001 Passes Safety Check in Phase 1/2 Trial of ALS</a></h1></li> <li><h1><a href="https://www.neurologylive.com/view/rimegepant-displays-safety-efficacy-study-adolescents-migraine">Rimegepant Displays Safety and Efficacy in Study of Adolescents With Migraine</a></h1></li> </ul><div> <br>Thanks for listening to the <em>NeurologyLive</em>® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit <a href="http://neurologylive.com/">neurologylive.com</a>.</div>

<div> <p>Welcome to the <em>NeurologyLive</em>® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.</p><p>In this Mind Moments episode, Jeff Chamberlain, PhD, joins the podcast during Duchenne Muscular Dystrophy Awareness Week to provide clinical and translational perspective on the evolving landscape of DMD biology and therapy. Chamberlain, professor at the University of Washington School of Medicine and Director of the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center in Seattle, reflects on aspects of Duchenne pathophysiology that may still be underappreciated, including evidence that disease processes begin earlier than once recognized and the growing importance of immunologic factors in shaping progression and therapeutic response. The conversation also explores how neuromuscular specialists should approach treatment timing and combination strategies as gene-targeted therapies expand, the evolving interpretation and limitations of biomarkers such as creatine kinase and dystrophin expression, and what emerging gene therapy platforms may signal for care heading into 2026 and beyond.</p><p><strong>Looking for more Neuromuscular discussion? Check out the </strong><strong><em>NeurologyLive</em></strong><strong>® </strong><a href="https://www.neurologylive.com/clinical/neuromuscular"><strong>Neuromuscular clinical focus page</strong></a><strong>.</strong></p><p>Episode Breakdown:</p></div><ul> <li> <strong>1:15</strong> – Underrecognized aspects of DMD pathophysiology, including early onset and immunologic drivers</li> <li> <strong>4:50</strong> – Treatment timing, sequencing, and the rationale for combination strategies</li> <li> <strong>8:00</strong> – Neurology News Minute</li> <li> <strong>10:30</strong> – Clinical trial and real-world implications of dystrophin and CK as biomarkers</li> <li> <strong>16:20</strong> – Anticipated gene therapy innovation and safety considerations heading into 2026</li> </ul><div><p><br>The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:</p></div><ul> <li><h1><a href="https://www.neurologylive.com/view/regenxbio-mps-ii-gene-therapy-rgx-121-crl">Regenxbio's MPS II Gene Therapy RGX-121 Hit With CRL</a></h1></li> <li><h1><a href="https://www.neurologylive.com/view/fda-accepts-nda-orexin-agonist-oveporexton-nt1-grants-priority-review">FDA Accepts New Drug Application for Orexin Agonist Oveporexton in Narcolepsy Type 1, Grants Priority Review</a></h1></li> <li><h1><a href="https://www.neurologylive.com/view/fda-expands-indication-pitolisant-treat-cataplexy-pediatric-narcolepsy">FDA Expands Indication for Pitolisant to Treat Cataplexy in Pediatric Narcolepsy</a></h1></li> </ul><div> <br>Thanks for listening to the <em>NeurologyLive</em>® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit <a href="http://neurologylive.com/">neurologylive.com</a>.</div>

<div> <p>Welcome to this special episode of the <em>NeurologyLive</em>® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.</p><p>In this special edition of <em>Mind Moments</em>, Shyam Prabhakaran, MD, MS, the James Nelson and Anna Louise Raymond Professor of Neurology and chair of the Department of Neurology at the <a href="https://www.uchicagomedicine.org/">University of Chicago Medicine</a>, joined the show to discuss the recent updates to the American Heart Association/American Stroke Association's guideline for the early management of acute ischemic stroke.  Prabhakaran clarified the main takeaways for clinicians and touched on details around endovascular thrombectomy care in pediatrics as well as treatment within and outside of the golden window.</p></div><h1>For <em>NeurologyLive</em>'s coverage of ISC 2026, head here: <a href="https://www.neurologylive.com/conferences/isc">International Stroke Conference (ISC)</a> </h1><div> <p>To read the new guidelines, head here: <a href="https://www.ahajournals.org/doi/10.1161/STR.0000000000000513"><strong>2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association</strong></a></p><p>Thanks for listening to the <em>NeurologyLive </em>Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit <a href="http://neurologylive.com/">neurologylive.com</a>.</p></div>